The genomic simplicity of differentiated cancers derived from thyroid follicular cells offers
unique insights into how oncogenic drivers impact tumour phenotype. Essentially, the main …

The advanced, metastatic differentiated thyroid cancers (DTCs) have a poor prognosis
mainly owing to radioactive iodine (RAI) refractoriness caused by decreased expression of …

Thyroid cancer is a common type of endocrine malignancy, and its incidence has been
steadily increasing in many regions of the world. Initiation and progression of thyroid cancer …

Objectives: Next-generation sequencing (NGS) allows for high-throughput sequencing
analysis of large regions of the human genome. We explored the use of targeted NGS for …

Purpose Cetuximab or panitumumab are effective in 10% to 20% unselected metastatic
colorectal cancer (CRC) patients. KRAS mutations account for approximately 30% to 40 …

This review—the first in a series concerning the biology of cancer—is a comprehensive
survey of oncogenes, tumor-suppressor genes, and microRNA genes in cancer cells. Work …

Genetic alteration is the driving force for thyroid tumorigenesis and progression, based upon
which novel approaches to the management of thyroid cancer can be developed. A recent …

In recent years, the T1799A B-type Raf kinase (BRAF) mutation in thyroid cancer has
received enthusiastic investigation, and significant progress has been made toward …

Advanced human thyroid cancers, particularly those that are refractory to treatment with
radioiodine (RAI), have a high prevalence of BRAF (v-raf murine sarcoma viral oncogene …

Patients with poorly differentiated thyroid cancers (PDTC), anaplastic thyroid cancers (ATC),
and radioactive iodine-refractory (RAIR) differentiated thyroid cancers have a high mortality …